2026-10-14T15:55:03Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33995691 2026-09-30T14:17:28Z category_58707 category_58326 category_58344 portal_1101 item_type_1 month_year_09_2026

<b>Infographic</b>: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE®-MASLD, a randomised, double-blind, placebo-controlled phase 3 trial Lee M. Kaplan (24746902) Elena Startseva (23060499) Carel W le Roux (8310600) Sean Wharton (23060484) Biykem Bozkurt (23060513) Daniel F. Mazo (22526686) Jessica von Schlippenbach (24399593) Sandra González-Maldonado (510312) Samina Ajaz Hussain (23060494) Guy Neff (21364047) Yaneicy Gonzalez-Rojas (24399725) Charles Smith (25110534) Ramy Younes (9870776) Arun J Sanyal (22238608) 4. HEALTH SCIENCES 3. BIOMEDICAL AND CLINICAL SCIENCES Clinical sciences Survodutide MASLD metabolic dysfunction-associated steatotic liver disease (MALSD) MASH obesity overweight liver fat content liver fat reduction liver health hepatology phase 3 trial SYNCHRONIZE-MASLD randomized trial placebo-controlled trial cardiometabolic health Body weight reduction MRI-PDFF Non-invasive testing fibrosis liver inflammation glucagon receptor agonist GLP-1 receptor agonist metabolic disease NCT06309992 Steatotic liver disease (SLD) <p dir="ltr">The above is a graphical abstract of the publication "Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE®-MASLD, a randomised, double-blind, placebo-controlled phase 3 trial", published in Nature Medicine (2026)</p> 2026-09-30T14:17:28Z Image Figure 10.60915/Boehringer-figshare.33995691.v2 https://figshare.com/articles/figure/Graphical_Abstract_Survodutide_in_adults_with_obesity_and_metabolic_dysfunction-associated_steatotic_liver_disease_SYNCHRONIZE_-MASLD_a_randomised_double-blind_placebo-controlled_phase_3_trial/33995691 CC BY 4.0